Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 882 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period C Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects

NCT04003402
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASP8062, Alcohol, ASP8062 Placebo, Alcohol Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
21 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)

NCT03528577
View directory record Official record
Conditions
Asthma
Interventions
Zero-dose, 90 mcg of PROAIR® HFA, 180 mcg of 90 mcg of PROAIR® HFA, 90 mcg of albuterol sulfate inhalation aerosol
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Miami Lakes, Florida • Bethesda, Maryland • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 30, 2026, 5:29 PM EDT
Active, not recruiting Not applicable Interventional

Impact of Powered Knee-Ankle Prosthesis Leg on Everyday Community Mobility and Social Interaction

NCT03204513
View directory record Official record
Conditions
Transfemoral Amputees
Interventions
Vanderbilt Powered Knee-Ankle Prosthesis, Microprocessor (MP) Knee Prosthesis
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 5:29 PM EDT
Terminated Phase 3 Interventional

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

NCT03926624
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Drug
Lead sponsor
Delta-Fly Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
39
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

NCT02018536
View directory record Official record
Conditions
Healthy
Interventions
GSK2336805 30 mg, GSK2336805 60 mg, GSK2336805 120 mg, TMC435 150 mg (Treatment A), GSK2336805 60 mg (Treatment B and part of Treatment C and D), TMC435 100 mg (part of Treatment C), TMC435 150 mg (part of treatment D)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants

NCT02307864
View directory record Official record
Conditions
Healthy
Interventions
Tramadol HCl, Moxifloxacin 400 mg, Tramadol HCl Placebo, Moxifloxacin Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Essential Oils for Enhancing QOL in ASD

NCT02543203
View directory record Official record
Conditions
Autism Spectrum Disorder, Quality of Life, Sleep, Anxiety
Interventions
Reconnect, Coconut oil Comparator
Biological
Lead sponsor
Jill Hollway
Other
Eligibility
3 Years to 9 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Addressing Health Disparities in Engagement, Retention, and Utilization of PrEP Among South Florida Women of Color

NCT05338996
View directory record Official record
Conditions
HIV Prevention, PrEP Adherence
Interventions
iENGAGE for PrEP
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Miami, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 30, 2026, 5:29 PM EDT
Terminated Phase 2 Interventional Results available

Vaccine Treatment of Kidney Cancer

NCT00089778
View directory record Official record
Conditions
Kidney Cancer
Interventions
117-126:Fibroblast growth factor 5 (FGF-5), Fibroblast growth factor 5 (FGF-5):172-176/217-220, IL-2
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants

NCT04909242
View directory record Official record
Conditions
Healthy Volunteers
Interventions
DZD9008, Placebo
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

NCT03379506
View directory record Official record
Conditions
HCV Infection
Interventions
EBR/GZR FDC Tablet, Placebo, Grazoprevir Oral Granules, Elbasvir Oral Granules
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
3 Years to 17 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
San Francisco, California • Orlando, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Results available

Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease

NCT00529035
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Interleukin-2
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

NCT03441984
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 30, 2026, 5:29 PM EDT
Recruiting Not applicable Interventional

Remote Cardiac Rehab for Adolescents With Congenital Heart Disease

NCT06015191
View directory record Official record
Conditions
Congenital Heart Disease in Children
Interventions
Remote Cardiac Rehabilitation, Active Control
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 19 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 30, 2026, 5:29 PM EDT
Not yet recruiting Phase 3 Interventional

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

NCT07670650
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
SAB-142, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 40 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study of LY2886721 Single Doses in Healthy Subjects

NCT01133405
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY2886721, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioavailability Study of MIV-711 Oral Formulations in Healthy Volunteers

NCT03443453
View directory record Official record
Conditions
Healthy
Interventions
MIV-711
Drug
Lead sponsor
Medivir
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules

NCT03801148
View directory record Official record
Conditions
Healthy Volunteers
Interventions
30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

NCT01392703
View directory record Official record
Conditions
Pharmacokinetic Study in Healthy Participants
Interventions
Dasatinib as tablets, Dasatinib as liquid, Dasatinib as dispersed tablets
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

NCT03649165
View directory record Official record
Conditions
Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Acetaminophen
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 30, 2026, 5:29 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Acute and Mild TBI Injury in Military and Civilian Population Using Advanced MR Imaging

NCT05101239
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
MRI imaging exam
Device
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Fort Belvoir, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 30, 2026, 5:29 PM EDT
Active, not recruiting Not applicable Interventional

C-Brace II Spinal Cord Injury

NCT03930056
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
C-Brace II, Traditional Care KAFO intervention
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants

NCT07641881
View directory record Official record
Conditions
Healthy Participants
Interventions
Casdatifan
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 30, 2026, 5:29 PM EDT
Completed Phase 2 Interventional

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

NCT01096043
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Strata 1 CXL-1020, Strata 2 CXL-1020, Strata 3 CXL-1020
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
15
States / cities
Gainesville, Florida • Jacksonville, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 30, 2026, 5:29 PM EDT